This document presents Prexton Therapeutics’ successful €8.7 million ($10 million) Series A fundraising round, co-led by Sunstone Capital and Ysios Capital, with continued support from MS Ventures. Prexton, a Swiss-based biopharmaceutical company founded in 2012, is dedicated to developing innovative therapies for central nervous system (CNS) disorders, with a strong focus on Parkinson’s disease.

The funds will support the development of novel small molecules that selectively target the metabotropic glutamate receptor 4 (mGluR4), offering a new therapeutic approach to improve motor complications while potentially reducing long-term side effects associated with dopaminergic treatments. Preclinical studies have shown promising results, positioning Prexton’s lead compound as a candidate to advance to clinical trials.

The document also provides insights into Parkinson’s disease prevalence, the limitations of current treatments, and the urgent need for innovative solutions. Additionally, it highlights the expertise of Prexton’s team and the strategic involvement of leading European venture capital firms committed to advancing breakthrough therapies in neuroscience.